Baillie Gifford & Co. Cuts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Baillie Gifford & Co. trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 17.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,040,259 shares of the biopharmaceutical company's stock after selling 846,741 shares during the quarter. Baillie Gifford & Co. owned approximately 3.13% of Alnylam Pharmaceuticals worth $950,713,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 3.2% in the third quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company's stock worth $589,209,000 after purchasing an additional 66,928 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Alnylam Pharmaceuticals by 3.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company's stock valued at $134,035,000 after purchasing an additional 16,756 shares during the period. Swiss National Bank raised its position in shares of Alnylam Pharmaceuticals by 0.3% in the third quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company's stock valued at $103,246,000 after purchasing an additional 1,000 shares during the period. Eagle Asset Management Inc. raised its position in shares of Alnylam Pharmaceuticals by 25.7% in the third quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company's stock valued at $85,889,000 after purchasing an additional 63,385 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 3.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock valued at $67,464,000 after purchasing an additional 8,462 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Performance

ALNY stock traded up $1.98 during trading hours on Thursday, hitting $252.49. 727,787 shares of the stock were exchanged, compared to its average volume of 695,015. The firm has a market capitalization of $32.69 billion, a P/E ratio of -116.36 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The company has a 50-day simple moving average of $254.04 and a two-hundred day simple moving average of $263.12.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.94 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares in the company, valued at approximately $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CMO Pushkal Garg sold 52,592 shares of the firm's stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares of the company's stock, valued at $3,416,865. This trade represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 81,356 shares of company stock worth $22,498,551. 1.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

ALNY has been the topic of several research analyst reports. Scotiabank lowered their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a "sector outperform" rating on the stock in a research note on Friday, February 14th. William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. Wolfe Research cut Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a report on Tuesday, November 12th. Chardan Capital reiterated a "buy" rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Finally, StockNews.com lowered Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, January 9th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $299.48.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.